

Giant cell tumor of zygoma: A case study of rare neoplasm

T Nagpal¹, N Gupta^{2*}, S Abrol³, H Charaniya⁴, R Raj⁵

¹Professor and Head, ²Senior Resident, ^{3,4,5}Resident, Department of Dhiraj General Hospital, Vadodara, INDIA.

Email: tjnagpal@rediffmail.com

Abstract

We have come across with a rare case of giant cell tumor of zygoma in a 27 year old male patient. The tumor was involving glenoid fossa, erosion of zygomatic bone. Tumor was resected completely followed by radiotherapy. Due to limited literature, it provoked us to do a case study.

Key Word: Giant cell tumor, Zygoma.

*Address for Correspondence:

Dr. N Gupta, Dhiraj General hospital, Sumandeep Vidhyapeeth University, Waghodia Road, Pipariya, Vadodara, Gujarat 391760

Email: tjnagpal@rediffmail.com

Received Date: 14/09/2018 Revised Date: 14/10/2018 Accepted Date: 20/11/2018

DOI: <https://doi.org/10.26611/1016832>

Access this article online

Quick Response Code:



Website:

www.medpulse.in

Accessed Date:
10 December 2018

INTRODUCTION

Giant cell tumor (GCT) of the bone occurs in one in a million people and accounts for approximately 3%-7% of primary bone tumors with most common sites at the epiphysis of long bones^{1,4}. Giant cell tumor has been classified as an aggressive benign lesion with malignant potential by the World Health Organization (WHO)⁵. GCTs arising in the head and neck region constitute approximately 2% of all GCTs, with the majority occurring in the sphenoid, ethmoid, or temporal bones^{6,7}. The other reported sites for this tumor in the head and neck include: parieto-occipital bones^{8,9}, maxilla¹⁰ and zygomatic bone^{11,12}. Giant cell tumor of zygoma is extremely rare with only 3 cases reported in the medical literature in the past as per our knowledge.

Table 1: Summary of patients with giant cell tumor of the zygomatic bone

S.N	Source	Age/sex	Primary site	Presenting symptoms	Treatment modality
1	Hafeez et al. (1964) [11]	32/male	Zygomatic bone	Preauricular swelling	Curettage followed by radiotherapy
2	Muszynski et al. [12] (1995)	12/male	Temporal and zygomatic bones	Facial nerve paralysis and facial swelling	Surgery followed by radiotherapy
3	Sethi et al. [13] (2005)	36/female	Zygomatic bone	Infraorbital swelling	Surgery
4	Tapan et al. (this study) [2018]	27/male	Zygomatic bone	Preauricular swelling	Surgery followed by radiotherapy

CASE REPORT

A 27 year old male patient came to Dhiraj hospital Pipariya, presented with left preauricular swelling and facial pain for 2 years. It was gradual in onset and progressive in nature. Physical examination revealed a 8x5 cm, hard, non-tender, oval and diffused swelling on

the left preauricular area with no lymphadenopathy. Computed tomography with contrast imaging revealed a multilocular expansile osteolytic lesion of size approximately 3.6 x 3.7 cm (in axial section) involving left zygomatic, petrous and squamous part of temporal bone. Patient was posted for tumour excision under

general anesthesia. Modified blairs incision extending to temoral region was taken. The tumor was extending medially to zygoma, inferior to glenoid fossa and condyl, superiorly to dural plate and laterally till temporal bone. Tumor was resected in toto with healthy margins including total parotidectomy, baring facial nerve. The

specimen was sent for histopathology which showed numerous osteoclast-like giant cells uniformly distributed throughout tumor. Many giant cells are larger than normal osteoclasts with numerous (>50) nuclei. Spindle and round / oval mononuclear cells were also present (Fig 5). Patient was sent for radiotherapy.



Figure 1: Pre operative picture




Figure 2: CT scan showing coronal and axial cut with contrast




Figure 3: operative picture




Figure 4: Specimen

Figure 5: Histopathology

DISCUSSION

GCTs are benign but locally aggressive neoplasms characterized by the presence of osteoclast-like giant cells admixed with epithelioid and spindle-shaped

mononuclear cells. GCTs are also referred to as osteoclastomas because of the resemblance of the giant cells to osteoclasts. GCT typically occurs in the metaphysis and epiphysis of long bones. GCTs of the head and neck are uncommon^{6,14,15}. Giant cell tumors

exhibit a peak age incidence between 20 and 30 years with a female preponderance¹⁶. The definitive treatment of GCTs requires surgical excision, with the extent of surgery dependent on the size and extent of the tumor. Up to 60% of GCTs recur if treated by simple curettage alone, whereas recurrence after wide resection is about 7%^{17,18}. Cryosurgery also has been used as an alternative treatment modality and Radiotherapy is usually reserved for lesions that are not amenable to surgical resection and cryotherapy. Although the older literature indicates that GCTs were radioresistant and prone to malignant transformation following radiotherapy, more current findings using supervoltage radiation indicate that GCTs are radioresponsive and not subject to increased incidence of sarcomatous transformation following radiation^{19,20,21}.

REFERENCES

1. Dahlin DC, Dupps RE, Johnson EW. Giant cell tumors: a study of 195 cases. *Cancer* 1970; 25: 1061-1070.
2. Emely WE. Giant cell tumor of sphenoid: a case report and review of the literature. *Arch Otolaryngol* 1971; 94: 369-374.
3. Epstein N, Whelan M, Reed D, Aleksic S. Giant cell tumor of the skull: a report of two cases. *Neurosurgery* 1982; 11: 263-267.
4. Findlay JM, Chiasson D, Hudson AR, Chui M. Giant cell tumor of the middle cranial fossa. *J Neurosurg* 1987; 66: 924-928.
5. Schazowicz F. Histological typing of bone tumours. Berlin: Springer-Verlag; 1993. p. 20_2
6. Saleh EA, Taibah AK, Naguib M, Aristegui M, Vassallo G, Landolfi M, et al. Giant cell tumor of the lateral skull base: a case report. *Otolaryngol Head Neck Surg.* 1994 Sep; 111(3 Pt 1):314-8.
7. Rosenbloom JS, Storper IS, Aviv JE, Hacin-Bey L, Bruce JN. Giant cell tumors of the jugular foramen. *Am J Otolaryngol.* 1999 May-Jun; 20(3):176-9.
8. Leonard J, Gokden M, Kyriakos M, Derdeyn CP, Rich KM. Malignant giant-cell tumour of the parietal bone: case report and review of the literature. *Neurosurgery* 2001; /48:/424_/9.
9. Harris AE, Beckner ME, Barnes L, Kassam A, Horowitz M. Giant cell tumour of the skull: a case report and review of the literature. *Surg Neurol* 2004; /61:/274_/7.
10. Mooney WW, Bridger GP, Baldwin M, Dorellan M. Recurrent giant cell tumour of the maxilla associated with both Paget's disease and primary hyperparathyroidism. *Aust N Z J Surg* 2003; /73:/863_/4.
11. Hafeez MA, Tandon PL, Singhal SL, Thakar SV. Giant cell tumour of the zygomatic bone. *J Indian Med Assoc* 1964; /42:/126_/7.
12. Muszynski P, Modrzejewski M, Kotarba E. Osteoclastoma of temporal and zygomatic bone. *Otolaryngol Pol* 1995; /49:/324_/8.
13. Ashwani Sethi, J.C. Passey, Sumit Mrig, Deepika Sareen & Prashant Sharma. Giant cell tumour (osteoclastoma) of the zygoma: An extremely unusual neoplasm. *Acta Otolaryngologica*, 2006; 126: 327_/329.
14. Bertoni F, Unni KK, Beabout JW, et al. Giant cell tumor of the skull. *Cancer* 1992; 70: 1124-32.
15. Smith GA, Ward PH. Giant cell lesions of the facial skeleton. *Arch Otolaryngol* 1978; 104: 186-90
16. Sharma RR, Mahapatra AK, Pawar SJ, Sousa J, Dev EJ. Cranio-spinal giant cell tumours: clinicoradiological analysis in a series of 11 cases. *J Clin Neurosci* 2002; /9:/41_/50.
17. Fechner RE, Mills SE. Giant cell lesions. In: Rosai J, Sobin LH, editors. *Tumors of the bones and joints*. Fascicle 8, 3rd series. Washington, DC: Armed Forces Institute of Pathology; 1993.
18. Ali MS. Metachronous multicentric giant cell tumour: a case report. *Indian J Cancer* 1997; /34:/169_/76
19. Marcove RC, Weis LD, Vaghaiwalla MR, et al. Cryosurgery in the treatment of giant cell tumors of bone: a report of 52 consecutive cases. *Cancer* 1978; 41:957-69.
20. Harwood AR, Fornasier VL, Rider WD. Supervoltage irradiation in the management of giant cell tumor of bone. *Radiology* 1977; 125:223-6.
21. Seider M, Rich TA, Ayala AG, et al. Giant cell tumor of bone: treatment with radiation therapy. *Radiology* 1986; 161:537-40.

Source of Support: None Declared
Conflict of Interest: None Declared